Nemaura Medical (OTC:NMRD) finished the European clinical trial program for its non-invasive glucose monitoring system earlier this month and reported that it’s preparing to submit the product for CE Mark clearance in the E.U.
The company’s clinical trial program in Europe included 75 patients who wore sugarBeat continuously for up to 14 hours over 7 consecutive days in both home and clinical settings.
Get the full story at our sister site, Drug Delivery Business News.
The post Nemaura readies CE Mark submission for non-invasive glucose monitor appeared first on MassDevice.
from MassDevice http://ift.tt/2EdKlqn
Cap comentari:
Publica un comentari a l'entrada